Influenza B virus, inactivated neuraminidase
Highest phase reached
Approved
Drug type
Vaccine component
First approval year
2007
- First approval year
- 2007
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Vaccine component
- Drug name
- Influenza B virus, inactivated neuraminidase
- influenza b virus inactivated neuraminidase component of fluad tetra
- influenza b virus inactivated neuraminidase component of flucelvax tetra
- influenza b virus inactivated neuraminidase component of optaflu
- Influenza b virus, inactivated neuraminidase component of fluad tetra
- Influenza b virus, inactivated neuraminidase component of flucelvax tetra
- Influenza b virus, inactivated neuraminidase component of optaflu
- influenza b virus inactivated neuraminidase
- Influenza b virus, inactivated neuraminidase
- ChEMBL ID
- CHEMBL6068385
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -ase; vir-
Mechanisms of action
- Mechanism
- Neuraminidase vaccine antigen
- Action type
- VACCINE_ANTIGEN
- Target
- Neuraminidase
- Protein identifier
- P03474
Open Targets mechanisms
- Mechanism
- Neuraminidase vaccine antigen
- Action type
- VACCINE ANTIGEN
- Target
- Neuraminidase
- Condition
- Vaccination
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004292
- Subject identifier
- D014611
- Condition
- Influenza, Human
- Highest recorded phase
- 4
- Condition identifier
- EFO:0007328
- Subject identifier
- D007251
- Condition identifier
- EFO_0007328
- Condition identifier
- EFO_0007411
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005812
- Highest recorded phase
- 4
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (47)
- A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older
- A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older
- A Study of Influenza Virus Vaccines in Children and Adults
- A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India
- A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy Subjects
- A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Healthy Adults
- Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination
- B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults
- Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
- Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older
- Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP
- Comparison of Three Licensed Influenza Vaccines
- Effect of High-Dose Quadrivalent Influenza Vaccine (Efluelda®) Versus Standard-Dose (QIV-SD), in Subjects 65 Years of Age and Older on Innate Immunity, Including Gene Expression
- Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers
- First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults
- Flucelvax Pregnancy Registry
- High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients
- High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
- High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients